These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 3838315)

  • 1. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation.
    Parker KA; Tollefsen DM
    J Biol Chem; 1985 Mar; 260(6):3501-5. PubMed ID: 3838315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition.
    Derechin VM; Blinder MA; Tollefsen DM
    J Biol Chem; 1990 Apr; 265(10):5623-8. PubMed ID: 2138609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells.
    McGuire EA; Tollefsen DM
    J Biol Chem; 1987 Jan; 262(1):169-75. PubMed ID: 3793724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of heparin cofactor II by dermatan sulfate.
    Tollefsen DM; Pestka CA; Monafo WJ
    J Biol Chem; 1983 Jun; 258(11):6713-6. PubMed ID: 6687888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin.
    Nagase H; Enjyoji K; Minamiguchi K; Kitazato KT; Kitazato K; Saito H; Kato H
    Blood; 1995 Mar; 85(6):1527-34. PubMed ID: 7888673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.
    Van Deerlin VM; Tollefsen DM
    J Biol Chem; 1991 Oct; 266(30):20223-31. PubMed ID: 1939083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
    Blinder MA; Tollefsen DM
    J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of meizothrombin and meizothrombin(desF1) by heparin cofactor II.
    Han JH; Côté HC; Tollefsen DM
    J Biol Chem; 1997 Nov; 272(45):28660-5. PubMed ID: 9353333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin inhibition by HCII in the presence of elastase-cleaved HCII and thrombin-HCII complex.
    Maekawa H; Sato H; Tollefsen DM
    Thromb Res; 2000 Dec; 100(5):443-51. PubMed ID: 11150588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of thrombin inhibition by heparin cofactor II and antithrombin in the presence of the ray (Raja radula) skin dermatan sulfate.
    Ben Mansour M; Dhahri M; Vénisse L; Jandrot-Perrus M; Chaubet F; Maaroufi RM
    Thromb Res; 2009 Apr; 123(6):902-8. PubMed ID: 19046760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist.
    Buchanan MR; Brister SJ
    Thromb Res; 2000 Sep; 99(6):603-12. PubMed ID: 10974347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure.
    Tollefsen DM; Pestka CA
    Blood; 1985 Oct; 66(4):769-74. PubMed ID: 4041618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
    Sheehan JP; Tollefsen DM; Sadler JE
    J Biol Chem; 1994 Dec; 269(52):32747-51. PubMed ID: 7806495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of basic residues of the A helix of heparin cofactor II to heparin- or dermatan sulfate-mediated thrombin inhibition.
    Hayakawa Y; Hirashima Y; Kurimoto M; Hayashi N; Hamada H; Kuwayama N; Endo S
    FEBS Lett; 2002 Jul; 522(1-3):147-50. PubMed ID: 12095635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II.
    Liaw PC; Austin RC; Fredenburgh JC; Stafford AR; Weitz JI
    J Biol Chem; 1999 Sep; 274(39):27597-604. PubMed ID: 10488098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin cofactor IIOslo. Mutation of Arg-189 to His decreases the affinity for dermatan sulfate.
    Blinder MA; Andersson TR; Abildgaard U; Tollefsen DM
    J Biol Chem; 1989 Mar; 264(9):5128-33. PubMed ID: 2647747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin cofactor II determination--levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation.
    Tran TH; Duckert F
    Thromb Haemost; 1984 Oct; 52(2):112-6. PubMed ID: 6395434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of chymotrypsin by heparin cofactor II.
    Church FC; Noyes CM; Griffith MJ
    Proc Natl Acad Sci U S A; 1985 Oct; 82(19):6431-4. PubMed ID: 3863104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Heparin cofactor II, a thrombin inhibitor with a still not clarified physiologic role].
    Rossi EB; Duboscq CL; Kordich LC
    Medicina (B Aires); 1999; 59(1):95-104. PubMed ID: 10349131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin.
    Holland CA; Henry AT; Whinna HC; Church FC
    FEBS Lett; 2000 Nov; 484(2):87-91. PubMed ID: 11068038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.